OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.

A Race Against Blindness (RAB) today announced the launch of its Spring 2026 national fundraiser, Two Winners, One Drive for Vision Research, in strategic partnership with the Foundation Fighting ...

We present one of the first comprehensive evaluations of predictive information derived from retinal fundus photographs, illustrating the potential and limitations of readily accessible and low-cost ...

Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal ...

Ocugen, Inc. (NASDAQ:OCGN) is one of the High-Flying Penny Stocks to Buy. On March 11, Ocugen, Inc. (NASDAQ:OCGN) was ...

Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with ...

Ahead of a string of local shows – including a performance at Arrow Street Arts in Cambridge this Saturday – the Reading ...

A 2026 company-issued report outlining Retina Clear's 'Red Root Hack' marketing narrative, ingredient research context, ...

Eye Cancer, Known Medically as Retinoblastoma, Is a Rare Eye Disease Retinoblastoma is a rare eye disease that primarily occurs in childhood and can affect one or both eyes. One of the most common ...

People with MS who carry the APOE4 gene variant show greater signs of nerve damage and cognitive decline than those who don't ...

An FDA complete response letter for idebenone in LHON indicates unresolved NDA deficiencies and necessitates additional data before approval can be reconsidered. Priority review status and a February ...

Genomics can help to identify people who are more likely to develop glaucoma potentially long before any symptoms of the disease appear. Instead ...